WO2012030371A1 - Immediate release drugs for high ph environments - Google Patents
Immediate release drugs for high ph environments Download PDFInfo
- Publication number
- WO2012030371A1 WO2012030371A1 PCT/US2011/000362 US2011000362W WO2012030371A1 WO 2012030371 A1 WO2012030371 A1 WO 2012030371A1 US 2011000362 W US2011000362 W US 2011000362W WO 2012030371 A1 WO2012030371 A1 WO 2012030371A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- oral dosage
- solid oral
- dosage pharmaceutical
- ion exchange
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to the use of weak acid ion exchange resins (IER) to create an immediate release (IR) drug delivery system using release enhancers to overcome the pH dependent release characteristics normally associated with weak acid resins.
- IER weak acid ion exchange resins
- Formulations containing weak acid ion exchange resins are frequently used for immediate release of pharmaceutical agents in a patient's stomach. However, release from weak acid resins is slowed and / or reduced at higher than normal stomach pH levels. High pH levels could occur if the patient is taking medications such as proton pump inhibitors (PPIs) or has a disease state that induces hypochlorhydria or achlorhydria. In either case, a weak acid formulation may not release the medicament at a rate or to an extent adequate to achieve the desired therapeutic effect.
- PPIs proton pump inhibitors
- prior art dosage forms lack the ability to provide the immediate release properties of weak acid IER formulations when administered to a patient with stomach pH environments at about 1.5 to 2.0 and above.
- weak acid resinates can be formulated to have immediate release characteristics at pH levels above about 1.5 to 2.0.
- the present invention creates a release enhancing weak acid resin drug formulation by adding a release enhancing agent to the formulation to increase the rate and extent of drug release from the formulation such that it meets an a priori definition of immediate release.
- Immediate release is defined as at least 80% release of a pharmaceutically active agent within 45 minutes in a standard dissolution apparatus according to the USP 31 NF 26 section 71 1.
- the invention is a solid oral dosage
- composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release enhancing agent.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin to form a weak acid ion exchange resinate (ii) a release enhancing agent; wherein said composition is capable of an immediate release of said at least one pharmaceutically active agent from said weak acid ion exchange resinate when administered to a patient with a stomach pH of at least about 1.5.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for oral administration.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having normal stomach acid pH of at least about 1.5. to 2.0.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having a an ailment selected from the group consisting of Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients selected from the group consisting of patients who have been administered a member of the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid, within the preceding 24 hours.
- the invention is a method of treating a patient for a condition with a pharmaceutically active agent effective for treating said condition, said method comprising orally administering a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release-enhancing agent
- the invention is a method of treating a patient with a stomach pH of at least about 1.5 comprising administration of the solid oral dosage composition of claim 1 wherein said administration results in immediate release of said pharmaceutically active agent from said weak acid ion exchange resinate.
- Figure 1 is a flow chart that illustrates a process for creating a drug/resin complex, the drug resination process.
- Figure 2 is a flow chart that illustrates a process for adding a coating to a drug resinate to enhance material flow during additional manufacturing processes.
- Figure 3 is a flow chart that illustrates a process for adding an extended release coating to a drug resinate.
- Figure 4 is a flow chart that illustrates a process for creating a second drug component which may be added to a drug resinate formulation.
- Figure 5 is a flow chart that illustrates a process for creating a release enhancer which may be added to a drug resinate formulation.
- Figure 6 is a flow chart that illustrates a process for creating an immediate release capsule dosage form containing a drug resinate and a release enhancing agent.
- Figure 7 is a flow chart that illustrates a process for creating an immediate release tablet dosage form containing a drug resinate and a release enhancing agent.
- Figure 8 is a flow chart that illustrates a process for creating an immediate release tablet dosage form containing a drug resinate, a second drug component and a release enhancing agent.
- Figure 9 is a flow chart that illustrates a process for creating an immediate release capsule dosage form containing an immediate release drug resinate, a second drug component and a release enhancing agent.
- Figure 10 is a flow chart that illustrates a process for creating a capsule dosage form containing an extended release drug resinate, an immediate release resinate component and a release enhancing agent.
- Figure 1 1 is a flow chart that illustrates a process for creating an extended release pseudoephedrine component by coating immediate release pseudoephedrine particles.
- Figure 12 is a flow chart that illustrates a process for creating a fixed combination ER tablet by combining IR and ER resinates along with IR and ER pseudoephedrine.
- Figure 13 is a flow chart that illustrates a process for creating a fixed combination ER capsule by combining IR and ER resinates along with IR and ER pseudoephedrine.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent.
- compositions of the invention are characterized by faster, and / or more complete, drug release compared to a weak acid resin formulation without the release enhancing agent in pH environments at or above about 1.5 to 2.0.
- the release- enhancing agent results in immediate release of the pharmaceutically active agent(s) from the weak acid ion exchange resin in pH environments at or above about 1.5 to 2.0.
- the pharmaceutical composition can be formulated, for example, as a capsule or compressed tablet.
- inventive compositions are preferably in a solid oral dosage form, such as a tablet, caplet, capsule, orally disintegrating tablet, powder, consumable film or any other dosage form, containing at least one pharmaceutical agent bound to an ion exchange resin and at least one release-enhancing agent.
- the composition is preferably swallowed without forming a liquid state of the active drug substance prior to ingestion through the oral cavity and into the gastric system.
- the invention includes compositions having a single pharmaceutically active agent and also fixed combination products containing more than one pharmaceutically active agent. Furthermore, the invention includes compositions including both an IR component and extended release (ER) component. In these embodiments, the IR component (as described above) can also be used as the nucleus to provide the extended release component through the use of an extended release coating.
- the drug release kinetics of weak acid resins can be affected by higher pH levels in the gastric fluid such that the rate and / or extent of drug release can be greatly reduced.
- Adding a release enhancing agent to a weak acid formulation is useful for assuring that the resinated drug is released from an IER formulation when stomach acid is reduced or eliminated (hypochlorhydria and achlorhydria) by disease states such as Helicobacter (H.) pylori infection or atrophic gastritis.
- a release enhancing agent with a strong affinity for the ionic resin can facilitate release of the resinated drug in abnormal human gastric fluid where the pH is much higher than normal due to the use of drugs such as proton pump inhibitors or the presence of disease states such as H. pylori infection or atrophic gastritis.
- Weak acid ion exchange resins useful in the invention include, for example, Amberlite IRP88 (CAS Registry Number 39394-76-5), and DOWEX MAC-3, but other weak acid ion exchange agents may be used.
- the release-enhancing agent can be, for example, an inorganic salt
- an organic base e.g.. thiamine, guanine, or cytosine
- a cationic surfactant e.g., cetyltrimethylammonium bromide (CTAB), denatonium benzoate, or benzalkonium chloride
- a non-ionic surfactant e.g., Tween 20 or Tween 80.
- the pharmaceutical composition can optionally include a second ion exchange resin.
- This second ion exchange resin is bound to one or more pharmaceutical agents and can be coated with a extended release coating, resulting in extended release of the pharmaceutically active agent(s) from the second ion exchange resin when administered to a patient.
- the second ion exchange resin can be bound to the same or different pharmaceutically active agent as the first ion exchange resin.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin to form a weak acid ion exchange resinate (ii) a release enhancing agent; wherein said composition is capable of an immediate release of said at least one pharmaceutically active agent from said weak acid ion exchange resinate when administered to a patient with a stomach pH of at least about 1.5, and preferably at least about 2.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for oral administration.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having normal stomach acid pH of at least about 1.5, and preferably at least about 2.
- the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having a an ailment selected from the group consisting of Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria.
- the invention is a solid oral dosage pharmaceutical composition
- a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients selected from the group consisting of patients who have been administered a member of the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid, within the preceding 24 hours.
- the invention is a method of treating a patient for a condition with a pharmaceutically active agent effective for treating said condition, said method comprising orally administering a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release-enhancing agent
- the invention is a method of treating a patient with a stomach pH of at least about 1.5, and preferably at least about 2 comprising administration of the solid oral dosage composition of claim 1 wherein said administration results in immediate release of said pharmaceutically active agent from said weak acid ion exchange resinate.
- release-enhancing agent is meant an agent that, when added to a weak acid drug resin formulation, increases the rate and / or extent of drug release than would otherwise occur without the release-enhancing agent in the same formulation.
- pharmaceutically active agent is meant agents other than food articles that are intended to diagnose, cure, mitigate, treat or prevent disease in man or other animals or that are intended to affect the structure or any function of the body of man or other animals that are physiologically acceptable.
- the agent could be a combination of drug therapies as well as a single agent.
- physiologically acceptable is meant those substances that are adequately tolerated without causing unacceptable negative side effects.
- ion exchange resin an insoluble solid matrix that carries exchangeable ions with either a positive or negative charge. The trapping of ions takes place only with simultaneous releasing of other ions. Ions are exchanged in stoichiometrically equivalent amounts of other ions with the same electrical charge when the ion exchange material is in contact with an electrolyte solution.
- inate is meant the complex formed when a drug exchanges an ion with a resin particle in the stoichiometric process described above and a drug/resin compound is formed.
- weak acid ion exchange resin in a weak acid resin the ionizable group introduced to the polymer is a carboxylic acid (COOH) as opposed to the sulfonic acid group (SO3H) used in strong acid resins. These resins behave similarly to weak organic acids so are weakly dissociated i.e. have fewer ions available for exchange.
- immediate release is meant that the pharmacologically active agent is released from the formulation immediately such that 80%, 85%, 90%, or even 95% of the pharmaceutically active agent in the formulation is released within 45 minutes when dissolution is measured according to the USP 31 NF 26 section 71 1.
- extended release is meant that the pharmaceutically active agent is released from the formulation at a controlled rate such that the formulation allows for a reduction in dosing frequency as compared to that presented by a conventional dosage form, e.g. an immediate release dosage form.
- the drug-containing weak acid ion exchange resins of the invention are formulated with release-enhancing agents. These release-enhancing agents result in immediate release of the drug from the weak acid ion exchange resins in pH environments at or above 2.0.
- suitable release-enhancing agents are:
- Fe 3+ (e.g. FeC )
- Ca 2+ e.g. CaCI 2
- Mg 2+ (e.g. MgCI 2 )
- Fe 2+ (e.g. FeCI 2 )
- CAB Cetyltrimethylammonium bromide
- Non-ionic agents are non-ionic agents:
- compositions for immediate release of pharmaceutically active agents using a weak acid ion exchange resin are:
- Anti-tussfves e.g., benzonatate, caramiphen edisylate, chlophedianol, codeine, dextromethorphan hydrobromide, hydrocodone, levopropoxyphene, morphine codeine, ethylmorphine, dihydrocodeine, benzylmorphine, laudanum, dihydroisocodeine, nicocodeine, nicodicodeine, hydrocodone, hydromorphone, acetyldihydrocodeine, thebacon, diamorphine (heroin), acetylmorphone, noscapine, and pholcodine.
- benzonatate caramiphen edisylate
- chlophedianol codeine
- codeine dextromethorphan hydrobromide
- hydrocodone levopropoxyphene
- morphine codeine ethylmorphine
- dihydrocodeine benzylmorphine
- Narcotic analgesics e.g., codeine, oxycodone, hydrocodone, diamorphine, pethidine, morphine, oxymorphone, nalorphine, naloxone, naltrexone, opium, hydromorphone, nicomorphine, dihydrocodeine, and papaveretum.
- Decongestants e.g., pseudoephedrine hydrochloride, phenylephrine bitartrate, phenylephrine hydrochloride and pseudoephedrine sulfate.
- Non-steroidal anti-inflammatory drugs e.g., aspirin, magnesium salicylate, diclofenac, etodolac, indometacin, nabumetone, sulindac, tolmetin, ibuprofen, ketoprofen, ,mefenamic acid, meclofenamic acid, phenylbutazone, piroxicam, meloxicam, celecoxib, parecoxib, rofecoxib, valdecoxib, and naproxen sodium.
- Anti-emetic drugs e.g., dolasetron, granisetron, ondansetron, tropisetron, palonosetron, mirtazapine, metoclopramide, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, and hydroxyzine.
- Anti-histamines e.g., diphenhydramine, loratadine, desloratadine, meclizine, fexofenadine, pheniramine, cetirizine, promethazine, brompheniramine, clemastine fumarate and chlorpheniramine.
- G Proton pump inhibitors (PPI), e.g., omeprazole, esomeprazole, pantoprazole, lansoprazole, and rabeprazole.
- PPI Proton pump inhibitors
- H H2 Antagonists, e.g., cimetidine, ranitidine, and famotidine.
- Anti-depressants e.g., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran, venlafaxine, atomoxetine, mazindol, reboxetine, viloxazine, amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, protriptyline, moclobemide, phenelzine, and selegiline.
- J Tranquilizers, e.g., amobarbital, pentobarbital, secobarbital, phenobarbital, clonazepam, diazepam, estazolam, flunitrazepam, lorazepam, midazolam, nitrazepam, oxazepam, triazolam, temazepam, chlordiazepoxide, and alprazolam.
- Tranquilizers e.g., amobarbital, pentobarbital, secobarbital, phenobarbital, clonazepam, diazepam, estazolam, flunitrazepam, lorazepam, midazolam, nitrazepam, oxazepam, triazolam, temazepam, chlordiazepoxide, and alprazolam.
- K Anti-convulsants, e.g., felbamate, carbamazepine, oxcarbazepine, vigabatrin, progabide, tiagabine, topiramate, gabapentin, pregabalin, ethotoin, and phenytoin.
- Anti-convulsants e.g., felbamate, carbamazepine, oxcarbazepine, vigabatrin, progabide, tiagabine, topiramate, gabapentin, pregabalin, ethotoin, and phenytoin.
- Hypnotics e.g., Zolpidem, zaleplon, zopiclone, and eszopiclone.
- M Muscle relaxants, e.g., methocarbamol, carisoprodol, chlorzoxazone, cyclobenzaprine, gabapentin, metaxalone, and orphenadrine.
- N Anti-psychotics, e.g., haloperidol, droperidol, chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, methotrimeprazine, pimozide, chlorprothixene, flupenthixol, thiothixene, zuclopenthixol, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, and paliperidone.
- chlorpromazine fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, methotrimeprazin
- Anti-microbials e.g., EDTA, zinc compounds, triclosan, domiphen, cetyl pyridium chloride, domiphen bromide, fluorides, alexidine, and octenidine.
- Anti-diarrheals e.g., bismuth subsalicylate and loperamide.
- R CNS stimulants, e.g., caffeine, cocaine, and amphetamines.
- S Attention Deficit and Hyperactivity Disorder drugs, e.g., methylphenidate, dextroamphetamine sulfate, amphetamine, and atomoxetine hydrochloride.
- the invention also includes methods and compositions for delivering combinations of pharmaceutically active compounds. EExamples of such combinations are:
- A an anti-tussive and an antihistamine
- F an anti-tussive and an antihistamine and an analgesic
- G an anti-tussive and an antihistamine and an NSAID
- H an anti-tussive and an antihistamine and a decongestant and an analgesic
- K a muscle relaxant and an analgesic and an NSAID
- M an H2 antagonist and an NSAID
- N a PPI and an analgesic
- O an H2 antagonist and an analgesic
- compositions of the invention include weak acid ion exchange resins.
- suitable ion exchange resins are, for example,
- DOWEX Mac-3 manufactured by DOW Chemical Dosage Forms Suitable dosage forms include tablets, capsules, orally disintegrating tablets, thin films, powders, beadlets, and the like
- compositions of the examples below are useful for oral administration for conditions such as normal stomach pH of about 1.5 to 2.0 or higher, Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria.
- the compositions of the examples are also useful for patients who have been administered a proton pump inhibitor, or a H2 receptor antagonist or an antacid within the preceding 24 hours.
- Example 1 Mono-substance hydrocodone IR coated intermediate.
- the process for creating the drug/resin complex and dosage form was as follows.
- the dried resinate was then formulated into hard gelatin capsules using the materials in the table above.
- the dried resinate was coated in a lab scale column coater using hydroxypropylmethylcellulose (HPMC) ,and triethyl citrate as a plasticizer. This is meant to enhance processing and protect the finished resin during subsequent capsule filling.
- HPMC coating is a type which has no effect on the dissolution rate and is added as a processing aid to enhance material flow during additional manufacturing steps.
- the coated resin along with the remaining ingredients were blended in a lab scale diffusional mixer and filled into empty capsule shells.
- Figure 1 is an illustration of the process for creating the resinate.
- Example 2 Formulation for a commercial hydrocodone product: Mono- substance IR dosage form, hard gelatin capsule.
- a mono-substance hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in EExample 1 and created with the processes described in Figure 1 and Figure 2. In the last process step, as shown in Figure 6, the coated resinate, the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
- Example 3 Formulation for a commercial: Mono-substance IR hydrocodone dosage form, compressed tablet.
- a mono-substance hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in EExample 1 and created with the processes described in Figure 1 and Figure 2. In the last process step, as shown in Figure 7, the coated resinate, the release enhancer pre-mix (prepared by a process shown in Figure 5) and the other excipients are blended and compressed into a tablet.
- Example 4 Mono-substance pseudoephedrine IR intermediate.
- a mono-substance pseudoephedrine IR intermediate could be prepared as illustrated with the materials shown in Example 4 and using the process outlined in Figure 4.
- Example 5 Formulation for a commercial product: Fixed combination dosage form using the IR hydrocodone component with a second medicinal agent, hard gelatin capsule.
- a fixed combination hydrocodone IR dosage form could be prepared as follows.
- the process begins with the coated hydrocodone resinate as specified in Example 1 and created with the processes described in Figure 1 and Figure 2.
- the second drug component (pseudoephedrine HCI) is created as an Intermediate with the materials shown in Example 4 and the process outlined in Figure 4.
- the coated resinate, the pseudoephedrine Intermediate and the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
- Example 6 Formulation for a commercial product: IR hydrocodone mono- substance with a second medicinal agent, compressed tablet.
- a fixed combination hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as outlined in Figure 2. The second drug component (pseudoephedrine HCI) is created as an Intermediate as specified in Example 4 and with the process shown Figure 4. In the last process step, as shown in Figure 8, the coated resinate, the Pseudoephedrine Intermediate component and the release enhancer pre-mix (prepared by a process shown in Figure 5) and the other excipients are blended and compressed into a tablet.
- Example 7 IR hydrocodone mono-substance component intermediate for filling hard gelatin capsules. Hydrocodone Resinate Coated IR 32mg
- a mono-substance hydrocodone IR intermediate for capsules could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in Example 1 and created with the processes described in Figure 1 and Figure 2. Next, the hydrocodone resinate intermediate, the release enhancing agent and the other excipients are blended to create an intermediate for filling capsules.
- Example 8 ER coated hydrocodone mono-substance component intermediate for filling hard gelatin capsules.
- a mono-substance hydrocodone ER intermediate could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in Example 1 and created with the process shown in Figure 2. Next, the immediate release coated resinate intermediate is further coated as shown in Figure 3 to create extended release (ER) intermediate particles.
- Example 9 Formulation for a commercial product: IR/ER hydrocodone encapsulation to fill a hard gelatin capsule to deliver 10 mg hydrocodone total.
- a mono-substance hydrocodone ER dosage form could be prepared as follows. Starting with the hydrocodone IR intermediate specified in Example 1 and the ER intermediate specified in Example 8, the process for filling a capsule to create an extended release capsule (ER) is shown in Figure 10. Notice that the process uses both the IR and ER coated hydrocodone intermediates from Examples 1 and 8, respectively.
- Example 10 Mono-substance codeine IR coated intermediate.
- a mono-substance codeine IR intermediate could be prepared as follows. The process begins with the excipient and the active ingredient as described in Example 1. The process for creating the drug resinate is illustrated in Figure 1. Next, the codeine resinate is coated to improve product flow as shown in Figure 2.
- Example 11 Formulation for a commercial product: IR Codeine Capsules. Codeine Resinate Coated IR 67mg
- a mono-substance codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. In the last process step, as shown in Figure 6, the coated codeine resinate, the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
- Example 12 Formulation for a commercial product: IR Codeine Tablets
- a mono-substance codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. In the last process step, as shown in Figure 7, the coated codeine resinate, the release enhancing agent and the other excipients are blended and compressed into a tablet.
- Example 13 Formulation for a commercial product: Fixed combination dosage form using the IR codeine component with a second medicinal agent, hard gelatin capsule
- a fixed combination codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. The second drug component (pseudoephedrine HCI) is created as an intermediate as shown in Example 4. In the last process step, as shown in Figure 9, the coated codeine resinate, the pseudoephedrine component intermediate and the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
- Example 14 Formulation for a commercial product: Fixed combination dosage form using the IR codeine component with a second medicinal agent, compressed tablet.
- a fixed combination codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. The second drug component (pseudoephedrine HCI) is created as an Intermediate with the materials shown in Example 4and the process outlined in Figure 4. In the last process step, as shown in Figure 8, the coated resinate, the second component Intermediate and the release enhancing agent and the other excipients are blended and compressed into a tablet.
- the second drug component prseudoephedrine HCI
- Example 15 IR codeine mono-substance component intermediate for filling hard gelatin capsules.
- a mono-substance codeine IR intermediate could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10 and created with the process outlined in Figure 2. . Next, the additional excipients are blended with the coated codeine resinate to produce the intermediate.
- Example 16 ER codeine mono-substance component intermediate for filling hard gelatin capsules.
- a mono-substance codeine ER intermediate could be prepared as follows. The process begins with the coated codeine resinate using the formulation specified in Example 10 and the process outlined in Figure 2. . Next, the immediate release coated codeine resinate intermediate is further coated using the process shown in Figure 3 to create an extended release (ER) intermediate.
- ER extended release
- Example 17 Formulation for a commercial product: IR/ER codeine encapsulation to fill a hard gelatin capsule to deliver 30 mg.
- a mono-substance codeine ER dosage form could be prepared as follows.
- the formulation for the IR codeine component is shown in Example 15 and the formulation for the ER codeine component is shown in Example 16.
- the process for filling a capsule with the IR and ER components used to create an extended release capsule (ER) is shown in Figure 10. Notice that the process uses both the IR and ER coated intermediates from Examples 15 and 16, respectively.
- a mono-substance pseudoephedrine ER intermediate could be prepared as follows. Starting with the active and inactive ingredients specified in this example 18, the process for creating the ER pseudoephedrine intermediate is illustrated in Figure 1 1. The composition of the pseudoephedrine IR component is taken from Example 4.
- Example 19 Formulation for a commercial product: IR/ER Hydrocodone, IR/ER Pseudoephedrine encapsulation to fill a hard gelatin capsule to deliver hydrocodone lOmg, pseudoephedrine 120mg IR Coated Hydrocodone 32mg
- a fixed combination hydrocodone ER dosage form could be prepared as follows.
- the process for filling a capsule to create an extended release capsule (ER) fixed combination capsule is shown in Figure 13. Notice that the process uses both the IR and ER coated hydrocodone intermediates from Examples 5 and 6, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
- Example 20 Formulation for a commercial product: IR/ER Hydrocodone, IR/ER Pseudoephedrine to deliver hydrocodone lOmg, pseudoephedrine 120mg, compressed tablet.
- a fixed combination hydrocodone ER dosage form could be prepared as follows.
- the process for creating a compressed tablet to create an extended release (ER), fixed combination tablet is shown in Figure 12. Notice that the process uses both the IR and ER coated hydrocodone intermediates for from Examples 5 and 6, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
- Example 21 Formulation for a commercial product: I /ER Codeine, IR/ER Pseudoephedrine encapsulation to fill a hard gelatin capsule to deliver codeine 30mg, pseudoephedrine 120mg.
- a fixed combination codeine ER dosage form could be prepared as follows.
- the process for filling a capsule to create an extended release capsule (ER) fixed combination capsule is shown in Figure 13. Notice that the process uses both the IR and ER coated intermediates for codeine as shown in Examples 15 and 16, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
- Example 22 Formulation for a commercial product: IR/ER Codeine, ER/ER Pseudoephedrine to deliver codeine 30mg, pseudoephedrine 120mg, compressed tablet.
- a fixed combination codeine ER dosage form could be prepared as follows.
- the process for creating a compressed tablet to create an extended release (ER), fixed combination tablet is shown in Figure 12. Notice that the process uses both the IR and ER coated intermediates for codeine as shown in Examples 15 and 16, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
- One process to manufacture the weak acid IER based products uses a modular approach in the preparation of the required intermediates. This allows maximal utilization of manufacturing capacity. It also assures minimal waste when processing controlled substances which are made to address selected therapeutic applications.
- the intermediate materials are used in the manufacture of the final dosage form.
- the flexibility of the intermediates when combined with commonly used excipients and the release-enhancing agent allows for an array of oral solid dosage forms.
- Two of the most commonly used in the art are outlined in this process section.
- the intermediate process and the dosage form preparation are shown here diagrammatically and fall into the following categories.
Abstract
Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments.
Description
IMMEDIATE RELEASE DRUGS FOR HIGH PH ENVIRONMENTS
BACKGROUND OF THE INVENTION
The present invention relates to the use of weak acid ion exchange resins (IER) to create an immediate release (IR) drug delivery system using release enhancers to overcome the pH dependent release characteristics normally associated with weak acid resins.
Formulations containing weak acid ion exchange resins are frequently used for immediate release of pharmaceutical agents in a patient's stomach. However, release from weak acid resins is slowed and / or reduced at higher than normal stomach pH levels. High pH levels could occur if the patient is taking medications such as proton pump inhibitors (PPIs) or has a disease state that induces hypochlorhydria or achlorhydria. In either case, a weak acid formulation may not release the medicament at a rate or to an extent adequate to achieve the desired therapeutic effect.
Approximately 60 million prescriptions were written for PPIs in 2006. Additionally, in the U.S., another 10 million people were reported to have self medicated with PPIs in 2008. Furthermore, about one in three adults used antacids on a regular basis. Collectively, these statistics suggest that close to 100 million people in the U.S. could be taking a drug that could significantly interfere with the release profile of a weak acid IER formulation. The history of prior art dosage forms indicates that a serious need exists for a novel and useful solid oral dosage form that provides an unexpected advancement in the science of IER dosage forms. For example, prior art dosage forms lack the ability to provide the immediate release properties of weak acid IER formulations when administered to a patient with stomach pH environments at about 1.5 to 2.0 and above. Surprisingly and unexpectedly, weak acid resinates can be formulated to have immediate release characteristics at pH levels above about 1.5 to 2.0. The present invention creates a release
enhancing weak acid resin drug formulation by adding a release enhancing agent to the formulation to increase the rate and extent of drug release from the formulation such that it meets an a priori definition of immediate release.
SUMMARY OF THE INVENTION
Surprisingly it has been found that by adding a release enhancing agent with a strong affinity for the ionic resin to a weak acid resin drug formulation, much more rapid and complete release of a resinated drug can be attained in abnormal gastric fluid than otherwise would occur without the presence of the release enhancing agent in abnormal human gastric fluid wherein the pH is much higher than normal due to the use of drugs such as PPI or the presence of disease states such as H. pylori or atrophic gastritis that can lead to hypochlorhydria and achlorhydria.
Thus, one can attain the rapid release properties of weak acid resinates while retaining the low sensitivity to pH change associated strong acid resins by adding a release enhancing agent to the weak acid drug formulation.
Immediate release is defined as at least 80% release of a pharmaceutically active agent within 45 minutes in a standard dissolution apparatus according to the USP 31 NF 26 section 71 1.
In a first embodiment, the invention is a solid oral dosage
pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release enhancing agent.
In a second embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin to form a weak acid ion exchange resinate (ii) a release enhancing agent; wherein said composition is capable of an immediate release of said at least one
pharmaceutically active agent from said weak acid ion exchange resinate when administered to a patient with a stomach pH of at least about 1.5.
In a third embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for oral administration.
In a fourth embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having normal stomach acid pH of at least about 1.5. to 2.0.
In a fifth embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having a an ailment selected from the group consisting of Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria.
In a sixth embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients selected from the group consisting of patients who have been administered a member of the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid, within the preceding 24 hours.
In a seventh embodiment, the invention is a method of treating a patient for a condition with a pharmaceutically active agent effective for treating said condition, said method comprising orally administering a solid oral dosage pharmaceutical composition comprising (i) at least one
pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release-enhancing agent
In an eighth embodiment, the invention is a method of treating a patient with a stomach pH of at least about 1.5 comprising administration of the solid oral dosage composition of claim 1 wherein said administration results in immediate release of said pharmaceutically active agent from said weak acid ion exchange resinate.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a flow chart that illustrates a process for creating a drug/resin complex, the drug resination process.
Figure 2 is a flow chart that illustrates a process for adding a coating to a drug resinate to enhance material flow during additional manufacturing processes.
Figure 3 is a flow chart that illustrates a process for adding an extended release coating to a drug resinate.
Figure 4 is a flow chart that illustrates a process for creating a second drug component which may be added to a drug resinate formulation.
Figure 5 is a flow chart that illustrates a process for creating a release enhancer which may be added to a drug resinate formulation.
Figure 6 is a flow chart that illustrates a process for creating an immediate release capsule dosage form containing a drug resinate and a release enhancing agent.
Figure 7 is a flow chart that illustrates a process for creating an immediate release tablet dosage form containing a drug resinate and a release enhancing agent.
Figure 8 is a flow chart that illustrates a process for creating an immediate release tablet dosage form containing a drug resinate, a second drug component and a release enhancing agent.
Figure 9 is a flow chart that illustrates a process for creating an immediate release capsule dosage form containing an immediate release drug resinate, a second drug component and a release enhancing agent.
Figure 10 is a flow chart that illustrates a process for creating a capsule dosage form containing an extended release drug resinate, an immediate release resinate component and a release enhancing agent.
Figure 1 1 is a flow chart that illustrates a process for creating an extended release pseudoephedrine component by coating immediate release pseudoephedrine particles.
Figure 12 is a flow chart that illustrates a process for creating a fixed combination ER tablet by combining IR and ER resinates along with IR and ER pseudoephedrine.
Figure 13 is a flow chart that illustrates a process for creating a fixed combination ER capsule by combining IR and ER resinates along with IR and ER pseudoephedrine.
DETAILED DESCRIPTION OF THE INVENTION
In a first embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent.
The pharmaceutical compositions of the invention are characterized by faster, and / or more complete, drug release compared to a weak acid resin formulation without the release enhancing agent in pH environments at or above about 1.5 to 2.0. When administered to a patient, the release- enhancing agent results in immediate release of the pharmaceutically active agent(s) from the weak acid ion exchange resin in pH environments at or above about 1.5 to 2.0.
The pharmaceutical composition can be formulated, for example, as a capsule or compressed tablet. The inventive compositions are preferably in
a solid oral dosage form, such as a tablet, caplet, capsule, orally disintegrating tablet, powder, consumable film or any other dosage form, containing at least one pharmaceutical agent bound to an ion exchange resin and at least one release-enhancing agent. The composition is preferably swallowed without forming a liquid state of the active drug substance prior to ingestion through the oral cavity and into the gastric system.
The invention includes compositions having a single pharmaceutically active agent and also fixed combination products containing more than one pharmaceutically active agent. Furthermore, the invention includes compositions including both an IR component and extended release (ER) component. In these embodiments, the IR component (as described above) can also be used as the nucleus to provide the extended release component through the use of an extended release coating.
The drug release kinetics of weak acid resins can be affected by higher pH levels in the gastric fluid such that the rate and / or extent of drug release can be greatly reduced. Adding a release enhancing agent to a weak acid formulation is useful for assuring that the resinated drug is released from an IER formulation when stomach acid is reduced or eliminated (hypochlorhydria and achlorhydria) by disease states such as Helicobacter (H.) pylori infection or atrophic gastritis.
By adding a release enhancing agent with a strong affinity for the ionic resin to the weak acid resin drug formulation can facilitate release of the resinated drug in abnormal human gastric fluid where the pH is much higher than normal due to the use of drugs such as proton pump inhibitors or the presence of disease states such as H. pylori infection or atrophic gastritis.
Weak acid ion exchange resins useful in the invention include, for example, Amberlite IRP88 (CAS Registry Number 39394-76-5), and DOWEX MAC-3, but other weak acid ion exchange agents may be used.
The release-enhancing agent can be, for example, an inorganic salt
(e.g., a salt including Fe3+, Ca2+, Mg2+, or Fe2+) an organic base (e.g..
thiamine, guanine, or cytosine), a cationic surfactant (e.g., cetyltrimethylammonium bromide (CTAB), denatonium benzoate, or benzalkonium chloride), or a non-ionic surfactant (e.g., Tween 20 or Tween 80).
The pharmaceutical composition can optionally include a second ion exchange resin. This second ion exchange resin is bound to one or more pharmaceutical agents and can be coated with a extended release coating, resulting in extended release of the pharmaceutically active agent(s) from the second ion exchange resin when administered to a patient. The second ion exchange resin can be bound to the same or different pharmaceutically active agent as the first ion exchange resin.
In a second embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin to form a weak acid ion exchange resinate (ii) a release enhancing agent; wherein said composition is capable of an immediate release of said at least one pharmaceutically active agent from said weak acid ion exchange resinate when administered to a patient with a stomach pH of at least about 1.5, and preferably at least about 2.
In a third embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for oral administration.
In a fourth embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having normal stomach acid pH of at least about 1.5, and preferably at least about 2.
In a fifth embodimen the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients having a an ailment selected from the group consisting of Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria.
In a sixth embodiment, the invention is a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release- enhancing agent, wherein said pharmaceutical composition is useful for patients selected from the group consisting of patients who have been administered a member of the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid, within the preceding 24 hours.
In a seventh embodiment, the invention is a method of treating a patient for a condition with a pharmaceutically active agent effective for treating said condition, said method comprising orally administering a solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release-enhancing agent
In an eighth embodiment, the invention is a method of treating a patient with a stomach pH of at least about 1.5, and preferably at least about 2 comprising administration of the solid oral dosage composition of claim 1 wherein said administration results in immediate release of said pharmaceutically active agent from said weak acid ion exchange resinate.
By "release-enhancing agent" is meant an agent that, when added to a weak acid drug resin formulation, increases the rate and / or extent of drug release than would otherwise occur without the release-enhancing agent in the same formulation.
By "pharmaceutically active agent" is meant agents other than food articles that are intended to diagnose, cure, mitigate, treat or prevent disease in man or other animals or that are intended to affect the structure or any function of the body of man or other animals that are physiologically acceptable. The agent could be a combination of drug therapies as well as a single agent.
By "physiologically acceptable" is meant those substances that are adequately tolerated without causing unacceptable negative side effects.
By "ion exchange resin" is meant an insoluble solid matrix that carries exchangeable ions with either a positive or negative charge. The trapping of ions takes place only with simultaneous releasing of other ions. Ions are exchanged in stoichiometrically equivalent amounts of other ions with the same electrical charge when the ion exchange material is in contact with an electrolyte solution.
By "resinate" is meant the complex formed when a drug exchanges an ion with a resin particle in the stoichiometric process described above and a drug/resin compound is formed.
By "weak acid ion exchange resin" is meant in a weak acid resin the ionizable group introduced to the polymer is a carboxylic acid (COOH) as opposed to the sulfonic acid group (SO3H) used in strong acid resins. These resins behave similarly to weak organic acids so are weakly dissociated i.e. have fewer ions available for exchange.
By "immediate release" is meant that the pharmacologically active agent is released from the formulation immediately such that 80%, 85%, 90%, or even 95% of the pharmaceutically active agent in the formulation is released within 45 minutes when dissolution is measured according to the USP 31 NF 26 section 71 1.
By "extended release" is meant that the pharmaceutically active agent is released from the formulation at a controlled rate such that the formulation allows for a reduction in dosing frequency as compared to that
presented by a conventional dosage form, e.g. an immediate release dosage form.
Release-Enhancing Agents
The drug-containing weak acid ion exchange resins of the invention are formulated with release-enhancing agents. These release-enhancing agents result in immediate release of the drug from the weak acid ion exchange resins in pH environments at or above 2.0. Examples of suitable release-enhancing agents are:
Inorganic agents:
Fe3+ (e.g. FeC )
Ca2+ (e.g. CaCI2)
Mg2+ (e.g. MgCI2)
Fe2+ (e.g. FeCI2)
Organic agents:
Thiamine
Guanine
Cytosine
Cationic agents:
Cetyltrimethylammonium bromide (CTAB)
Benzalkonium chloride
Denatonium benzoate (Bitrex)
Non-ionic agents:
Polysorbate 20 (Tween 20)
Polysorbate 80 (Tween 80)
Pharmaceutically Active Agents
The invention features methods and compositions for immediate release of pharmaceutically active agents using a weak acid ion exchange resin. Examples of such pharmaceutically active agents suitable for the compounds and methods of the inventions are:
A: Anti-tussfves, e.g., benzonatate, caramiphen edisylate, chlophedianol, codeine, dextromethorphan hydrobromide, hydrocodone, levopropoxyphene, morphine codeine, ethylmorphine, dihydrocodeine, benzylmorphine, laudanum, dihydroisocodeine, nicocodeine, nicodicodeine, hydrocodone, hydromorphone, acetyldihydrocodeine, thebacon, diamorphine (heroin), acetylmorphone, noscapine, and pholcodine.
B: Narcotic analgesics, e.g., codeine, oxycodone, hydrocodone, diamorphine, pethidine, morphine, oxymorphone, nalorphine, naloxone, naltrexone, opium, hydromorphone, nicomorphine, dihydrocodeine, and papaveretum.
C: Decongestants, e.g., pseudoephedrine hydrochloride, phenylephrine bitartrate, phenylephrine hydrochloride and pseudoephedrine sulfate.
D: Non-steroidal anti-inflammatory drugs, e.g., aspirin, magnesium salicylate, diclofenac, etodolac, indometacin, nabumetone, sulindac, tolmetin, ibuprofen, ketoprofen, ,mefenamic acid, meclofenamic acid, phenylbutazone, piroxicam, meloxicam, celecoxib, parecoxib, rofecoxib, valdecoxib, and naproxen sodium.
E: Anti-emetic drugs, e.g., dolasetron, granisetron, ondansetron, tropisetron, palonosetron, mirtazapine, metoclopramide, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, and hydroxyzine.
F: Anti-histamines, e.g., diphenhydramine, loratadine, desloratadine, meclizine, fexofenadine, pheniramine, cetirizine, promethazine, brompheniramine, clemastine fumarate and chlorpheniramine.
G: Proton pump inhibitors (PPI), e.g., omeprazole, esomeprazole, pantoprazole, lansoprazole, and rabeprazole.
H: H2 Antagonists, e.g., cimetidine, ranitidine, and famotidine.
I: Anti-depressants, e.g., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran, venlafaxine, atomoxetine, mazindol, reboxetine, viloxazine, amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, protriptyline, moclobemide, phenelzine, and selegiline.
J: Tranquilizers, e.g., amobarbital, pentobarbital, secobarbital, phenobarbital, clonazepam, diazepam, estazolam, flunitrazepam, lorazepam, midazolam, nitrazepam, oxazepam, triazolam, temazepam, chlordiazepoxide, and alprazolam.
K: Anti-convulsants, e.g., felbamate, carbamazepine, oxcarbazepine, vigabatrin, progabide, tiagabine, topiramate, gabapentin, pregabalin, ethotoin, and phenytoin.
L: Hypnotics, e.g., Zolpidem, zaleplon, zopiclone, and eszopiclone.
M: Muscle relaxants, e.g., methocarbamol, carisoprodol, chlorzoxazone, cyclobenzaprine, gabapentin, metaxalone, and orphenadrine.
N: Anti-psychotics, e.g., haloperidol, droperidol, chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, methotrimeprazine, pimozide, chlorprothixene, flupenthixol, thiothixene, zuclopenthixol, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, and paliperidone.
O: Anti-microbials, e.g., EDTA, zinc compounds, triclosan, domiphen, cetyl pyridium chloride, domiphen bromide, fluorides, alexidine, and octenidine.
P: Anti-diarrheals, e.g., bismuth subsalicylate and loperamide.
R: CNS stimulants, e.g., caffeine, cocaine, and amphetamines.
S: Attention Deficit and Hyperactivity Disorder drugs, e.g., methylphenidate, dextroamphetamine sulfate, amphetamine, and atomoxetine hydrochloride.
The invention also includes methods and compositions for delivering combinations of pharmaceutically active compounds. EExamples of such combinations are:
A: an anti-tussive and an antihistamine
B: an anti-tussive and a decongestant
C: an anti-tussive and an analgesic
D: an anti-tussive and an NSAID
E: an anti-tussive and an antihistamine and a decongestant
F: an anti-tussive and an antihistamine and an analgesic
G: an anti-tussive and an antihistamine and an NSAID
H: an anti-tussive and an antihistamine and a decongestant and an analgesic
I: a muscle relaxant and an analgesic
J: a muscle relaxant and an NSAID
K: a muscle relaxant and an analgesic and an NSAID
L: a PPI and an NSAID
M: an H2 antagonist and an NSAID
N: a PPI and an analgesic
O: an H2 antagonist and an analgesic
Ion Exchange Resins
The compositions of the invention include weak acid ion exchange resins. Examples of suitable ion exchange resins are, for example,
A: Amberlite IRP88 (CAS Registry Number 39394-76-5) manufactured by DOW Chemical
B: DOWEX Mac-3 manufactured by DOW Chemical Dosage Forms
Suitable dosage forms include tablets, capsules, orally disintegrating tablets, thin films, powders, beadlets, and the like
EXAMPLES
Each of the compositions of the examples below are useful for oral administration for conditions such as normal stomach pH of about 1.5 to 2.0 or higher, Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria. The compositions of the examples are also useful for patients who have been administered a proton pump inhibitor, or a H2 receptor antagonist or an antacid within the preceding 24 hours.
Example 1: Mono-substance hydrocodone IR coated intermediate.
* Equivalent to Hydrocodone Bitartrate lOmg.
The process for creating the drug/resin complex and dosage form was as follows.
500mg of IRP-88 from Rohm and Haas (currently DOW) were added to deionized water (2.5 L) which had been heated to 85°C. The resin and water were mixed using a magnetic stirring bar until a uniform suspension was obtained. 150mg of Hydrocodone Bitartrate was made into a solution in deionized water and then added to the resin slurry and mixed in the primary vessel with continued mixing for 4.0 hours at 85°C to create the hydrocodone resinate. The slurry was vacuum filtered to separate the resinate from the water. The resin particles were washed three times by re-suspending the
particles in 5 liters of deionized water maintained at 85°C. The resulting washed particles were filtered and allowed to cool for 12 hours. This process was repeated in order to generate adequate amounts of the hydrocodone resinate to prepare the number of capsules required for dissolution testing. Care was taken during the cooling process to avoid cake formation by periodically mixing the resinate bed with a glass stirring rod. The resinate was then dried using a lab scale fluid bed dryer set at 55°C inlet temperature. Drying was continued until a residual moisture content of 2.0% was obtained. Drug loading was tested and showed approximately 409% drug load or approximately 40mg of hydrocodone per 100 mg of resinate.
The dried resinate was then formulated into hard gelatin capsules using the materials in the table above. The dried resinate was coated in a lab scale column coater using hydroxypropylmethylcellulose (HPMC) ,and triethyl citrate as a plasticizer. This is meant to enhance processing and protect the finished resin during subsequent capsule filling. The HPMC coating is a type which has no effect on the dissolution rate and is added as a processing aid to enhance material flow during additional manufacturing steps. The coated resin along with the remaining ingredients were blended in a lab scale diffusional mixer and filled into empty capsule shells.
Figure 1 is an illustration of the process for creating the resinate.
Example 2: Formulation for a commercial hydrocodone product: Mono- substance IR dosage form, hard gelatin capsule.
* Equivalent to Hydrocodone Bitartrate lOmg.
A mono-substance hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in EExample 1 and created with the processes described in Figure 1 and Figure 2. In the last process step, as shown in Figure 6, the coated resinate, the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
Example 3: Formulation for a commercial: Mono-substance IR hydrocodone dosage form, compressed tablet.
* Equivalent to Hydrocodone Bitartrate lOmg
A mono-substance hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in EExample 1 and created with the processes described in Figure 1 and Figure 2. In the last process step, as shown in Figure 7, the coated resinate, the release enhancer pre-mix (prepared by a process shown in Figure 5) and the other excipients are blended and compressed into a tablet.
Example 4: Mono-substance pseudoephedrine IR intermediate.
HPMC 6 cps 20mg
Total Dosage Form Weight 358mg
A mono-substance pseudoephedrine IR intermediate could be prepared as illustrated with the materials shown in Example 4 and using the process outlined in Figure 4.
Example 5: Formulation for a commercial product: Fixed combination dosage form using the IR hydrocodone component with a second medicinal agent, hard gelatin capsule.
* Equivalent to Hydrocodone Bitartrate 1 Omg
** Equivalent to Pseudoephedrine HCI 60mg
A fixed combination hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in Example 1 and created with the processes described in Figure 1 and Figure 2. The second drug component (pseudoephedrine HCI) is created as an Intermediate with the materials shown in Example 4 and the process outlined in Figure 4. In the last process step, as shown in Figure 9, the coated
resinate, the pseudoephedrine Intermediate and the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules. Example 6: Formulation for a commercial product: IR hydrocodone mono- substance with a second medicinal agent, compressed tablet.
* Equivalent to Hydrocodone Bitartrate lOmg
Equivalent to Pseudoephedrine HCI 60mg A fixed combination hydrocodone IR dosage form could be prepared as follows. The process begins with the coated hydrocodone resinate as outlined in Figure 2. The second drug component (pseudoephedrine HCI) is created as an Intermediate as specified in Example 4 and with the process shown Figure 4. In the last process step, as shown in Figure 8, the coated resinate, the Pseudoephedrine Intermediate component and the release enhancer pre-mix (prepared by a process shown in Figure 5) and the other excipients are blended and compressed into a tablet.
Example 7: IR hydrocodone mono-substance component intermediate for filling hard gelatin capsules.
Hydrocodone Resinate Coated IR 32mg
Intermediate*
Release enhancing agent 15mg
Magnesium Stearate 2mg
Colloidal Silicon Dioxide 3mg
IR component weight 52mg
* Equivalent to Hydrocodone Bitartrate lOmg
A mono-substance hydrocodone IR intermediate for capsules could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in Example 1 and created with the processes described in Figure 1 and Figure 2. Next, the hydrocodone resinate intermediate, the release enhancing agent and the other excipients are blended to create an intermediate for filling capsules.
Example 8: ER coated hydrocodone mono-substance component intermediate for filling hard gelatin capsules.
* Equivalent to Hydrocodone Bitartrate lOmg
A mono-substance hydrocodone ER intermediate could be prepared as follows. The process begins with the coated hydrocodone resinate as specified in Example 1 and created with the process shown in Figure 2. Next, the immediate release coated resinate intermediate is further coated as shown in Figure 3 to create extended release (ER) intermediate particles.
Example 9: Formulation for a commercial product: IR/ER hydrocodone encapsulation to fill a hard gelatin capsule to deliver 10 mg hydrocodone total.
* Equivalent to Hydrocodone Bitartrate lOmg
A mono-substance hydrocodone ER dosage form could be prepared as follows. Starting with the hydrocodone IR intermediate specified in Example 1 and the ER intermediate specified in Example 8, the process for filling a capsule to create an extended release capsule (ER) is shown in Figure 10. Notice that the process uses both the IR and ER coated hydrocodone intermediates from Examples 1 and 8, respectively.
Example 10: Mono-substance codeine IR coated intermediate.
* Equivalent to Codeine Phosphate 15mg. A mono-substance codeine IR intermediate could be prepared as follows. The process begins with the excipient and the active ingredient as described in Example 1. The process for creating the drug resinate is illustrated in Figure 1. Next, the codeine resinate is coated to improve product flow as shown in Figure 2.
Example 11: Formulation for a commercial product: IR Codeine Capsules.
Codeine Resinate Coated IR 67mg
Intermediate*
Release enhancing agent 15mg
Magnesium Stearate 2mg
Colloidal Silicon Dioxide 3mg
Empty Capsule Shell #3 48mg
Total Dosage Form Weight 135mg
* Equivalent to Codeine Phosphate 15mg.
A mono-substance codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. In the last process step, as shown in Figure 6, the coated codeine resinate, the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
Example 12: Formulation for a commercial product: IR Codeine Tablets
* Equivalent to Codeine Phosphate 15mg
A mono-substance codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. In the last process step, as shown in Figure 7, the coated codeine resinate, the release enhancing agent and the other excipients are blended and compressed into a tablet.
Example 13: Formulation for a commercial product: Fixed combination dosage form using the IR codeine component with a second medicinal agent, hard gelatin capsule
* Equivalent to Codeine Phosphate 15mg
** Equivalent to Pseudoephedrine HCI 60mg
A fixed combination codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. The second drug component (pseudoephedrine HCI) is created as an intermediate as shown in Example 4. In the last process step, as shown in Figure 9, the coated codeine resinate, the pseudoephedrine component intermediate and the release enhancing agent and the other excipients are blended and filled into hard gelatin capsules.
Example 14: Formulation for a commercial product: Fixed combination dosage form using the IR codeine component with a second medicinal agent, compressed tablet.
Equivalent to Codeine Phosphate 15mg
**Equivalent to Pseudoephedrine HCI 60mg
A fixed combination codeine IR dosage form could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10. The second drug component (pseudoephedrine HCI) is created as an Intermediate with the materials shown in Example 4and the process outlined in Figure 4. In the last process step, as shown in Figure 8, the coated resinate, the second component Intermediate and the release enhancing agent and the other excipients are blended and compressed into a tablet.
Example 15: IR codeine mono-substance component intermediate for filling hard gelatin capsules.
* Equivalent to Codeine Phosphate 15mg
A mono-substance codeine IR intermediate could be prepared as follows. The process begins with the coated codeine resinate as specified in Example 10 and created with the process outlined in Figure 2. . Next, the
additional excipients are blended with the coated codeine resinate to produce the intermediate.
Example 16: ER codeine mono-substance component intermediate for filling hard gelatin capsules.
* Equivalent to Codeine Phosphate 15mg
A mono-substance codeine ER intermediate could be prepared as follows. The process begins with the coated codeine resinate using the formulation specified in Example 10 and the process outlined in Figure 2. . Next, the immediate release coated codeine resinate intermediate is further coated using the process shown in Figure 3 to create an extended release (ER) intermediate.
Example 17: Formulation for a commercial product: IR/ER codeine encapsulation to fill a hard gelatin capsule to deliver 30 mg.
* Equivalent to Codeine Phosphate 15mg
A mono-substance codeine ER dosage form could be prepared as follows. The formulation for the IR codeine component is shown in Example 15 and the formulation for the ER codeine component is shown in Example 16. The process for filling a capsule with the IR and ER components used to create an extended release capsule (ER) is shown in Figure 10. Notice that the process uses both the IR and ER coated intermediates from Examples 15 and 16, respectively. Example 18: ER coated pseudoephedrine component intermediate for filling hard gelatin capsules.
*Equivalent to Pseudoephedrine HCI 60mg
A mono-substance pseudoephedrine ER intermediate could be prepared as follows. Starting with the active and inactive ingredients specified in this example 18, the process for creating the ER pseudoephedrine intermediate is illustrated in Figure 1 1. The composition of the pseudoephedrine IR component is taken from Example 4.
Example 19: Formulation for a commercial product: IR/ER Hydrocodone, IR/ER Pseudoephedrine encapsulation to fill a hard gelatin capsule to deliver hydrocodone lOmg, pseudoephedrine 120mg
IR Coated Hydrocodone 32mg
component weight*
ER Coated Hydrocodone 62mg
component weight*
IR Pseudoephedrine component 358mg
weight**
ER pseudoephedrine component 388mg
weight**
Empty Capsule Shell #00 130mg
Total Dosage Form Weight 970mg
*Equivalent to lOmg hydrocodone
**Equivalent to 60mg pseudoephedrine HCI
A fixed combination hydrocodone ER dosage form could be prepared as follows. The process for filling a capsule to create an extended release capsule (ER) fixed combination capsule is shown in Figure 13. Notice that the process uses both the IR and ER coated hydrocodone intermediates from Examples 5 and 6, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively. Example 20: Formulation for a commercial product: IR/ER Hydrocodone, IR/ER Pseudoephedrine to deliver hydrocodone lOmg, pseudoephedrine 120mg, compressed tablet.
*Equivalent to lOmg hydrocodone
**Equivalent to 60mg pseudoephedrine HCI
A fixed combination hydrocodone ER dosage form could be prepared as follows. The process for creating a compressed tablet to create an extended release (ER), fixed combination tablet is shown in Figure 12. Notice that the process uses both the IR and ER coated hydrocodone intermediates for from Examples 5 and 6, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
Example 21: Formulation for a commercial product: I /ER Codeine, IR/ER Pseudoephedrine encapsulation to fill a hard gelatin capsule to deliver codeine 30mg, pseudoephedrine 120mg.
*Equivalent to 15mg codeine
**Equivalent to 60mg pseudoephedrine HCI
A fixed combination codeine ER dosage form could be prepared as follows. The process for filling a capsule to create an extended release capsule (ER) fixed combination capsule is shown in Figure 13. Notice that the process uses both the IR and ER coated intermediates for codeine as shown in Examples 15 and 16, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
Example 22: Formulation for a commercial product: IR/ER Codeine, ER/ER Pseudoephedrine to deliver codeine 30mg, pseudoephedrine 120mg, compressed tablet.
*Equivalent to 15mg codeine
**Equivalent to 60mg pseudoephedrine HCI
A fixed combination codeine ER dosage form could be prepared as follows. The process for creating a compressed tablet to create an extended release (ER), fixed combination tablet is shown in Figure 12. Notice that the process uses both the IR and ER coated intermediates for codeine as shown in Examples 15 and 16, respectively and both the IR and ER pseudoephedrine intermediates from Examples 4 and 15, respectively.
Formulation process
One process to manufacture the weak acid IER based products uses a modular approach in the preparation of the required intermediates. This allows maximal utilization of manufacturing capacity. It also assures minimal waste when processing controlled substances which are made to address selected therapeutic applications.
The intermediate materials are used in the manufacture of the final dosage form. The flexibility of the intermediates when combined with commonly used excipients and the release-enhancing agent allows for an array of oral solid dosage forms. Two of the most commonly used in the art are outlined in this process section.
The intermediate process and the dosage form preparation are shown here diagrammatically and fall into the following categories.
Intermediate Process Categories:
Resination of the Active Ingredient
Immediate Release (IR) Resin Coating
Extended release (ER) Resin Coating
Fixed Combination Second Component
Release Enhancer Pre-Mix
Dosage Form Process Categories:
Mono Substance IR Hard Gelatin Capsule
Mono Substance IR Compressed Tablet
Fixed Combination using the IR Resin Compressed Tablet
Fixed Combination using the IR Resin Hard Gelatin Capsule
Extended release Mono Substance Hard Gelatin Capsule
OTHER EMBODIMENTS
All publications, patent applications, and patents mentioned in this specification are herein incorporated by reference.
Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific desired embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the fields of medicine, immunology, pharmacology, endocrinology, or related fields are intended to be within the scope of the invention.
Claims
1. A solid oral dosage pharmaceutical composition comprising (i) at least one pharmaceutically active agent bound to a weak acid ion exchange resin and (ii) a release-enhancing agent.
2. The solid oral dosage pharmaceutical composition of claim 1 , wherein said composition is capable of immediate release of said at least one pharmaceutically active agent from said weak acid ion exchange resinate when administered to a patient with a stomach pH of at least about 1.5.
3. The solid oral dosage pharmaceutical composition of claim 1 , wherein said weak acid ion exchange resin is selected from the group consisting of a resin terminated in a carbonic acid moiety, Amberlite IRP88 or DOWEX MAC-3.3.
4. The solid oral dosage pharmaceutical composition of claim 1 , wherein said release-enhancing agent is selected from the group consisting of an inorganic salt, an organic base, a cationic surfactant, and a non-ionic surfactant.
5 The solid oral dosage pharmaceutical composition of claim 1 useful for oral administration.
6. The solid oral dosage pharmaceutical composition of claim 1 useful for patients having stomach acid pH at least about 1.5.
7. The solid oral dosage pharmaceutical composition of claim 1 , useful for patients having a condition selected from the group consisting of Helicobacter pylori infection and atrophic gastritis
8. The solid oral dosage pharmaceutical composition of claim 1 useful for administration to a patient within 24 hours of administration to said patient of a compound selected from the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid.
9. The solid oral dosage pharmaceutical composition of claim 1 useful for administration to a patient having a condition selected from the group consisting of hypochlorhydria and achlorhydria in the stomach.
10. The solid oral dosage pharmaceutical composition of claim 4, wherein said release-enhancing agent is an inorganic salt comprising an ion selected from the group consisting of Fe3+, Ca2+, Mg2+, and Fe2+.
1 1. The solid oral dosage pharmaceutical composition of claim 4, wherein said release-enhancing agent is an organic base selected from the group consisting of thiamine, guanine, and cytosine.
12. The solid oral dosage pharmaceutical composition of claim 4, wherein said release-enhancing agent is a cationic surfactant selected from the group consisting of cetyltrimethylammonium bromide (CTAB), denatonium benzoate, and benzalkonium chloride.
13. The solid oral dosage pharmaceutical composition of claim 4, wherein said release-enhancing agent is a non-ionic surfactant selected from the group consisting of Tween 20 and Tween 80.
14. The solid oral dosage pharmaceutical composition of claim 1 , wherein said composition is formulated as a member of the group consisting of a capsule, a powder, a thin film, a caplet and a tablet.
15. The solid oral dosage pharmaceutical composition of claim 14, wherein said composition is formulated as a capsule.
16. The solid oral dosage pharmaceutical composition of claim 14, wherein said composition is formulated as a tablet.
17. The solid oral dosage pharmaceutical composition of claim 16, comprising from about l mg to about lOmg of hydrocodone and from about 5mg to about lOOmg of CaCI2.
18. The solid oral dosage pharmaceutical composition of claim 17, comprising from about 30mg to about 60mg pseudoephedrine hydrochloride.
19. The solid oral dosage pharmaceutical composition of claim 16, comprising an immediate release component and an extended release component; wherein said immediate release component includes from about 1 mg to about lOmg hydrocodone bound to said first weak acid ion exchange resin, from about 5mg to lOOmg of CaCI2 and about 30mg to 60mg pseudoephedrine hydrochloride; and wherein said extended release component includes from about l mg to about lOmg hydrocodone, and from about 80 mg to about 120mg of pseudoephedrine hydrochloride.
20. The solid oral dosage pharmaceutical composition of claim 15, comprising about l mg to lOmg hydrocodone and about 5mg to lOOmg of CaCI2.
21.The solid oral dosage pharmaceutical composition of claim 15, comprising from about l mg to about lOmg hydrocodone bound to said first weak acid ion exchange resin, about 5mg to lOOmg mg of CaCI2 and about 30mg to 60mg pseudoephedrine hydrochloride.
22. The solid oral dosage pharmaceutical composition of claim 1, wherein at least two pharmaceutically active agents are bound to said first weak acid ion exchange resin.
23. The solid oral dosage pharmaceutical composition of claim 1 , further comprising a second ion exchange resin; wherein said second ion exchange resin is bound to a pharmaceutically active agent and is coated with an extended release coating.
24. The solid oral dosage pharmaceutical composition of claim 23, wherein said second ion exchange resin is bound to the same pharmaceutically active agent as the first weak acid ion exchange resin.
25. The solid oral dosage pharmaceutical composition of claim 1 , comprising an immediate release component and an extended release component, said immediate release component including from about l mg to about lOmg hydrocodone bound to said first weak acid ion exchange resin, from about 5mg to about lOOmg of CaCI2 and about from 30mg to about 60mg pseudoephedrine hydrochloride, said extended release component including from about l mg to about lOmg hydrocodone, and from about 80mg to about 120mg of pseudoephedrine hydrochloride.
26. The solid oral dosage pharmaceutical composition of claim 1 , comprising an immediate release component and an extended release component, said immediate release component including from about 5mg to about 15mg codeine bound to said first weak acid ion exchange resin, from about 15mg to about 120mg of CaCI2, and from about 30mg to about 60mg pseudoephedrine hydrochloride, said extended release component comprising from about 5mg to about 15 mg codeine and from about 80mg to aboutl20mg of pseudoephedrine.
27. The solid oral dosage pharmaceutical composition of claim 1 , comprising from about 5mg to aboutl 5mg codeine bound to said first weak acid ion exchange resin and from about 15mg to about 120mg of CaCI2; and wherein said composition is formulated as a capsule.
28. The solid oral dosage pharmaceutical composition of claim 1 , comprising from about 5mg to aboutl 5mg codeine bound to said first weak acid ion exchange resin and from about 15mg to about 120mg of CaCI2; and wherein said composition is formulated as a tablet.
29. The solid oral dosage pharmaceutical composition of claim 1 , comprising from about 5mg to about 15mg codeine bound to said first weak acid ion exchange resin, from about 15mg to about 120mg of CaCI2 and from about 30mg to about 60mg pseudoephedrine hydrochloride; wherein said composition is formulated as a capsule.
30. The solid oral dosage pharmaceutical composition of claim 1 , said composition further comprising from about 5mg to about 15mg codeine bound to said first weak acid ion exchange resin, from about 15mg to about 120mg of CaCI2 and from about 30mg to about 60mg pseudoephedrine hydrochloride; wherein said composition is formulated as a tablet.
31. A method of treating a patient for a condition with a pharmaceutically active agent effective for treating said condition, said method comprising orally administering the composition of claim 1.
32. A method of treating a patient with a stomach pH of at least about 1.5 comprising administration of the solid oral dosage composition of claim 1 wherein said administration results in immediate release of said pharmaceutically active agent from said weak acid ion exchange resinate.
33. A method of treating a patient having a first condition and a second condition with a pharmaceutically active agent effective for treating said second condition, said method comprising the step of administering the solid oral dosage pharmaceutical composition of claim 1 , wherein said first condition is selected from the group consisting of Helicobacter pylori infection, atrophic gastritis, hypochlorhydria and achlorhydria in the stomach; and wherein said second condition is a condition other than said first condition.
34. The method of claim 33, wherein the patient has within the past 24 hours been administered a compound selected from the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid.
35. A method of delivering a pharmaceutically active agent to a patient, said method comprising orally administering the composition of claim 1 and a compound selected from the group consisting of a proton pump inhibitor, an H2 receptor antagonist, and an antacid, wherein said administration results in immediate release of said pharmaceutically active agent from said weak acid ion exchange resinate; and wherein said composition of claim 1 is administered within 24 hours of said proton pump inhibitor, H2 receptor antagonist, or antacid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/807,434 | 2010-09-03 | ||
US12/807,434 US8187617B2 (en) | 2009-09-11 | 2010-09-03 | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012030371A1 true WO2012030371A1 (en) | 2012-03-08 |
Family
ID=43731170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/000362 WO2012030371A1 (en) | 2010-09-03 | 2011-02-28 | Immediate release drugs for high ph environments |
Country Status (2)
Country | Link |
---|---|
US (1) | US8187617B2 (en) |
WO (1) | WO2012030371A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI447859B (en) * | 2012-03-12 | 2014-08-01 | Inotera Memories Inc | Shallow trench isolation in dynamic random access memory and manufacturing method thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130177520A1 (en) * | 2009-12-31 | 2013-07-11 | Ranbaxy Laboratories Limited | Taste masked dosage forms of bitter tasting anti-retroviral drugs |
US8617602B2 (en) * | 2010-09-03 | 2013-12-31 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
WO2012167878A1 (en) | 2011-06-08 | 2012-12-13 | Lts Lohmann Therapie-Systeme Ag | Edible oral strip or wafer dosage form containing ion exchange resin for taste masking |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004614A (en) * | 1988-08-26 | 1991-04-02 | Forum Chemicals Ltd. | Controlled release device with an impermeable coating having an orifice for release of drug |
US5041390A (en) * | 1988-08-11 | 1991-08-20 | Skov Per S | Method and means for allergy diagnosis |
US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
US20080311201A1 (en) * | 2007-06-12 | 2008-12-18 | Lee Der-Yang | Modified release solid or semi-solid dosage forms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9402029D0 (en) | 1994-02-03 | 1994-03-30 | Smithkline Beecham Plc | Novel formulation |
US5811126A (en) * | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
US20030068276A1 (en) * | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20100092562A1 (en) * | 2002-11-26 | 2010-04-15 | Hollenbeck R Gary | Sustained-release drug delivery compositions and methods |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
DE602005020796D1 (en) * | 2004-07-22 | 2010-06-02 | Bend Res Inc | TASTE-COATING FORMULATION WITH A RETARDANT AGGREGATE FORMULATION AND / OR QUICKLY SOLUBLE CYCLODEXTRIN |
US20080118570A1 (en) * | 2006-11-20 | 2008-05-22 | Zhi Liu | Polymer coated drug-ion exchange resins and methods |
-
2010
- 2010-09-03 US US12/807,434 patent/US8187617B2/en active Active
-
2011
- 2011-02-28 WO PCT/US2011/000362 patent/WO2012030371A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041390A (en) * | 1988-08-11 | 1991-08-20 | Skov Per S | Method and means for allergy diagnosis |
US5004614A (en) * | 1988-08-26 | 1991-04-02 | Forum Chemicals Ltd. | Controlled release device with an impermeable coating having an orifice for release of drug |
US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
US20080311201A1 (en) * | 2007-06-12 | 2008-12-18 | Lee Der-Yang | Modified release solid or semi-solid dosage forms |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI447859B (en) * | 2012-03-12 | 2014-08-01 | Inotera Memories Inc | Shallow trench isolation in dynamic random access memory and manufacturing method thereof |
Also Published As
Publication number | Publication date |
---|---|
US8187617B2 (en) | 2012-05-29 |
US20110065742A1 (en) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8617602B2 (en) | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments | |
US11890267B2 (en) | Benzonatate modified release solid tablets and capsules | |
US9867797B2 (en) | Benzonatate modified release solid tablets and capsules | |
US20140186437A1 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
US9211292B2 (en) | Preventing or reducing drug abuse and overdose events | |
US8187617B2 (en) | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments | |
US8357398B2 (en) | Benzonatate compositions and methods of use | |
WO2014145195A1 (en) | Pharmaceuticals comprising a ph-dependent component and ph-raising agent | |
US8808743B2 (en) | Benzonatate compositions and methods of use | |
US20230158008A1 (en) | Methods and compositions for self-regulated release of active pharmaceutical ingredients | |
US20180071278A1 (en) | Anti-overingestion dosage forms | |
US20100273822A1 (en) | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11822237 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11822237 Country of ref document: EP Kind code of ref document: A1 |